董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathryn Henry | 女 | Independent Director | 59 | 未披露 | 未持股 | 2025-04-30 |
| Cheng Yin Pan | 男 | Independent Director | 36 | 未披露 | 未持股 | 2025-04-30 |
| Yeung Danny Sheng Wu | 男 | Director, Chairperson and Chief Executive Officer | 46 | 未披露 | 未持股 | 2025-04-30 |
| David Eric Vanderveen | 男 | Director and President of Americas | 56 | 未披露 | 未持股 | 2025-04-30 |
| Chiu Wing Kwan Winnie | 女 | Independent Director | 45 | 未披露 | 未持股 | 2025-04-30 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yeung Danny Sheng Wu | 男 | Director, Chairperson and Chief Executive Officer | 46 | 未披露 | 未持股 | 2025-04-30 |
| Tzang Chi Hung Lawrence | 男 | Chief Scientific Officer | 51 | 未披露 | 未持股 | 2025-04-30 |
| Lo Hoi Chun | 男 | Chief Financial Officer | 40 | 未披露 | 未持股 | 2025-04-30 |
| Senthil Kumar Sundaram | 男 | Chief Clinical Officer | 51 | 未披露 | 未持股 | 2025-04-30 |
| Joel Neoh | 男 | Chief Consumer Officer and Managing Director for CircleDNA | 41 | 未披露 | 未持股 | 2025-04-30 |
董事简历
中英对照 |  中文 |  英文- Kathryn Henry
-
Kathryn Henry,自2016年1月起成为公司董事会成员。自2015年起,Ms. Henry担任零售和技术公司的战略顾问,此外还为风投,和咨询公司提供执行层面的指导。2010年至2014年,Ms. Henry曾担任lululemon后勤和经销部首席信息官。Ms. Henry监督公司所有全球信息和技术业务。2010年加入公司前,Ms. Henry曾在Gap, Inc任职,担任国际 IT和Gap北美地区副总裁兼首席信息官以及重要国际举措的系统支持。根据与lululemon athletica达成的支持协议Ms. Henry被Dennis J. Wilson任命为公司董事会成员,Mr. Wilson和某些实体公司附属于Advent International。
Kathryn Henry,has been a member of board of directors since January 2016. She was a co-founder and early investor in LightBrite and served as its CEO from 2022 to 2023. From 2015 to 2022, she provided strategic consulting to retail and technology firms. Ms. Henry previously served as chief information officer, logistics & distribution of lululemon from 2010 to 2014 and held executive roles at Gap, Inc. Levi Strauss & Co. She currently serves on the board of directors of Prenetics Global Limited. - Kathryn Henry,自2016年1月起成为公司董事会成员。自2015年起,Ms. Henry担任零售和技术公司的战略顾问,此外还为风投,和咨询公司提供执行层面的指导。2010年至2014年,Ms. Henry曾担任lululemon后勤和经销部首席信息官。Ms. Henry监督公司所有全球信息和技术业务。2010年加入公司前,Ms. Henry曾在Gap, Inc任职,担任国际 IT和Gap北美地区副总裁兼首席信息官以及重要国际举措的系统支持。根据与lululemon athletica达成的支持协议Ms. Henry被Dennis J. Wilson任命为公司董事会成员,Mr. Wilson和某些实体公司附属于Advent International。
- Kathryn Henry,has been a member of board of directors since January 2016. She was a co-founder and early investor in LightBrite and served as its CEO from 2022 to 2023. From 2015 to 2022, she provided strategic consulting to retail and technology firms. Ms. Henry previously served as chief information officer, logistics & distribution of lululemon from 2010 to 2014 and held executive roles at Gap, Inc. Levi Strauss & Co. She currently serves on the board of directors of Prenetics Global Limited.
- Cheng Yin Pan
-
我们的首席执行官兼董事Cheng Yin Pan目前是C Ventures的管理合伙人,在那里他领导该公司的热门交易,并积极参与医疗保健、消费者和技术领域的大型风险资本和私募股权投资。程先生被猎云网评为2020年“中国20大最杰出投资者”,帮助执行了对上述“独角兽”的许多投资,例如Xpeng Motors,NIO,JD Logistics,Gojek,FTA,小红书和Pony.ai。在程先生的领导下,C Ventures还投资了3D视觉图形渲染引擎GritWorld,该投资在2019年被授予ChinaVenture的“AI&大数据十大交易”。郑先生亦为淡马锡控股附属公司Vertex Sea Fund的顾问委员会成员,以及香港创业投资及私募股权协会创业委员会成员。Cheng先生还自2016年3月起担任NWD总经理。在担任现职之前,Cheng先生是Bank of America Merrill Lynch和Standard Chartered Bank的投资银行家。程先生在大中华地区的交易单包括(其中包括)药明生物港交所5.1亿美元香港上市:2017年2269、2015年33亿美元私有化药明康德、2014年淡马锡57亿美元投资屈臣氏、21亿美元收购ING在香港的保险业务等重大企业融资交易,2013年澳门和泰国。Cheng先生持有香港中文大学(The Chinese University of Hong Kong)的数量金融学荣誉学士学位。
Cheng Yin Pan,is the Vice Chairman of the Board of Directors and Chief Executive Officer of Youngtimers AG, a Switzerland-listed global asset management firm (SIX: YTME), since January 2025, and Managing Director of C Capital since March 2016. Under his leadership, C Capital has made significant strides in the investment landscape, focusing on transformative opportunities across various sectors. With extensive experience in venture capital and private equity, Mr. Cheng has played a pivotal role in high-profile investments, including CASETiFY, the fastest-growing global tech accessories brand; XiaoPeng (NYSE: XPEV), a leading Chinese electric vehicle manufacturer; Animoca brands, a multinational blockchain technology; NOTHING, a UK-based consumer electronics manufacturer; Lalamove, a prominent Chinese on-demand logistics firm. Mr. Cheng is an independent director of Prenetics and holds a Non-executive Director position at Ocean Line Port Development Limited (8502.HK). In addition to his operational roles, Mr. Cheng actively contributes to the community as a committee member of Hong Kong Trade Development Council Mainland Business Advisory Committee and the Venture Committee of Hong Kong Venture Capital and Private Equity Association. He is also a director and committee member of the LRC Charitable Foundation (LRCCF). Prior to C Capital, Mr. Cheng hones his expertise as an investment banker at Bank of Americal Merrill Lynch and Standard Chartered Bank, where he was involved in landmark transactions such as the US$3.3 billion take-private of WuXi Pharma Tech, Temasek's US$5.7 billion investment in Watson's and the US$2.1 billion acquisition of ING's insurance business in Hong Kong, Macau and Thailand. Mr. Cheng holds a bachelor's degree in Quantitative Finance with honors from the Chinese University of Hong Kong. He is a member of CPA Australia. - 我们的首席执行官兼董事Cheng Yin Pan目前是C Ventures的管理合伙人,在那里他领导该公司的热门交易,并积极参与医疗保健、消费者和技术领域的大型风险资本和私募股权投资。程先生被猎云网评为2020年“中国20大最杰出投资者”,帮助执行了对上述“独角兽”的许多投资,例如Xpeng Motors,NIO,JD Logistics,Gojek,FTA,小红书和Pony.ai。在程先生的领导下,C Ventures还投资了3D视觉图形渲染引擎GritWorld,该投资在2019年被授予ChinaVenture的“AI&大数据十大交易”。郑先生亦为淡马锡控股附属公司Vertex Sea Fund的顾问委员会成员,以及香港创业投资及私募股权协会创业委员会成员。Cheng先生还自2016年3月起担任NWD总经理。在担任现职之前,Cheng先生是Bank of America Merrill Lynch和Standard Chartered Bank的投资银行家。程先生在大中华地区的交易单包括(其中包括)药明生物港交所5.1亿美元香港上市:2017年2269、2015年33亿美元私有化药明康德、2014年淡马锡57亿美元投资屈臣氏、21亿美元收购ING在香港的保险业务等重大企业融资交易,2013年澳门和泰国。Cheng先生持有香港中文大学(The Chinese University of Hong Kong)的数量金融学荣誉学士学位。
- Cheng Yin Pan,is the Vice Chairman of the Board of Directors and Chief Executive Officer of Youngtimers AG, a Switzerland-listed global asset management firm (SIX: YTME), since January 2025, and Managing Director of C Capital since March 2016. Under his leadership, C Capital has made significant strides in the investment landscape, focusing on transformative opportunities across various sectors. With extensive experience in venture capital and private equity, Mr. Cheng has played a pivotal role in high-profile investments, including CASETiFY, the fastest-growing global tech accessories brand; XiaoPeng (NYSE: XPEV), a leading Chinese electric vehicle manufacturer; Animoca brands, a multinational blockchain technology; NOTHING, a UK-based consumer electronics manufacturer; Lalamove, a prominent Chinese on-demand logistics firm. Mr. Cheng is an independent director of Prenetics and holds a Non-executive Director position at Ocean Line Port Development Limited (8502.HK). In addition to his operational roles, Mr. Cheng actively contributes to the community as a committee member of Hong Kong Trade Development Council Mainland Business Advisory Committee and the Venture Committee of Hong Kong Venture Capital and Private Equity Association. He is also a director and committee member of the LRC Charitable Foundation (LRCCF). Prior to C Capital, Mr. Cheng hones his expertise as an investment banker at Bank of Americal Merrill Lynch and Standard Chartered Bank, where he was involved in landmark transactions such as the US$3.3 billion take-private of WuXi Pharma Tech, Temasek's US$5.7 billion investment in Watson's and the US$2.1 billion acquisition of ING's insurance business in Hong Kong, Macau and Thailand. Mr. Cheng holds a bachelor's degree in Quantitative Finance with honors from the Chinese University of Hong Kong. He is a member of CPA Australia.
- Yeung Danny Sheng Wu
-
Yeung Danny 吴胜,是联合创始人。自2014年业务启动以来,杨先生一直担任首席执行官和董事。杨先生进入医疗保健的旅程始于利用他广泛的创业生涯为社会带来影响。从第一天起,杨先生的愿景就是始终将Prenetics Global Limited打造成一家全球性的健康集团,招募最优秀的人才,并给予每个人掌控自身健康的力量。杨先生认为,医疗保健的未来是让医疗保健去中心化,让医疗保健更接近全球数百万人。在共同创立Prenetics Global Limited公司之前,Yeung先生是SXE Ventures的创始合伙人,曾领导对基因检测公司和Honey Science的多项投资,后者于2019年被PayPal以40亿美元收购。杨先生还曾在2010年创立uBuyiBuy,该公司随后被Groupon收购。在2014年初离开Groupon之前,杨先生曾担任Groupon东亚地区的首席执行官,使其成为该地区最大的电子商务公司。杨先生的创业之旅始于25岁,当时他冒险将香港甜品连锁店“回流山”特许经营进入美国。在退出汇流山后,杨先生成功涉足款待家具,并与MGM在全球范围内执行了数百万美元的项目。
Yeung Danny Sheng Wu,is co-founder. Since business inception in 2014, Mr. Yeung has served as Chief Executive Officer and director. Mr. Yeung's journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung's vision from day 1 was to always turn Prenetics Global Limited into a global health group, recruiting the best talent, and to give everyone the power to be in control of their own health. Prior to co-founding Prenetics Global Limited company, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by PayPal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung's entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain "Hui Lau Shan" into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi- million-dollar projects with MGM globally. - Yeung Danny 吴胜,是联合创始人。自2014年业务启动以来,杨先生一直担任首席执行官和董事。杨先生进入医疗保健的旅程始于利用他广泛的创业生涯为社会带来影响。从第一天起,杨先生的愿景就是始终将Prenetics Global Limited打造成一家全球性的健康集团,招募最优秀的人才,并给予每个人掌控自身健康的力量。杨先生认为,医疗保健的未来是让医疗保健去中心化,让医疗保健更接近全球数百万人。在共同创立Prenetics Global Limited公司之前,Yeung先生是SXE Ventures的创始合伙人,曾领导对基因检测公司和Honey Science的多项投资,后者于2019年被PayPal以40亿美元收购。杨先生还曾在2010年创立uBuyiBuy,该公司随后被Groupon收购。在2014年初离开Groupon之前,杨先生曾担任Groupon东亚地区的首席执行官,使其成为该地区最大的电子商务公司。杨先生的创业之旅始于25岁,当时他冒险将香港甜品连锁店“回流山”特许经营进入美国。在退出汇流山后,杨先生成功涉足款待家具,并与MGM在全球范围内执行了数百万美元的项目。
- Yeung Danny Sheng Wu,is co-founder. Since business inception in 2014, Mr. Yeung has served as Chief Executive Officer and director. Mr. Yeung's journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung's vision from day 1 was to always turn Prenetics Global Limited into a global health group, recruiting the best talent, and to give everyone the power to be in control of their own health. Prior to co-founding Prenetics Global Limited company, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by PayPal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung's entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain "Hui Lau Shan" into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi- million-dollar projects with MGM globally.
- David Eric Vanderveen
-
大卫·埃里克·范德文(David Eric Vanderveen)在饮料、营养和技术领域拥有30年的成功业绩记录,在私营和上市公司都引领了颠覆性变革。从2022年直到最近,他担任Nirvana Water Sciences的CEO,在那里他发展了一支行业饮料、功能饮料和补充剂专家团队,以转变品牌、产品组合、上市战略和业务的执行。从2002年到2015年,Vanderveen先生是XS Worldwide的创始人和首席执行官,该公司拥有能量饮料和运动营养产品组合。XS与安利公司合作,成为全球最大直销商增长最快的业务板块和品类,年销售额超过4亿美元,在60多个国家进行分销。XS于2015年被出售给安利,范德文先生在安利担任XS品牌副总裁兼全球总经理,在2018年实现了最大收益。Vanderveen先生还是RX3 Growth Partners的顾问和有限合伙人,RX3 Growth Partners是一家私募股权公司,与消费品牌和其他领先的投资公司合作,通过利用其独特的运动员、名人和思想领袖的影响者基础实现价值最大化,并且是LLB Global Fund的普通合伙人,这是一家与法国律师事务所Lazareff Le Bars合作的国际仲裁基金。
David Eric Vanderveen,has had a successful 30-year track record in beverage, nutrition, and technology, leading disruptive change at both private and public companies. From 2022 until recently, he was CEO of Nirvana Water Sciences, where he developed a team of industry beverage, functional beverage, and supplement experts to transform the brand, product portfolio, go-to-market strategy, and execution of the business. From 2002 to 2015, Mr. Vanderveen was the founder and CEO of XS Worldwide, a company with a portfolio of energy drinks and sports nutrition products. XS partnered with Amway Corporation and became the fastest-growing business segment and category for the world's largest direct seller, reaching annual sales over $400 million with distribution in more than 60 countries. XS was sold to Amway in 2015, where Mr. Vanderveen served as Vice President and Global General Manager for the XS brand, achieving maximum earn-out through 2018. Mr. Vanderveen is also an advisor and limited partner at RX3 Growth Partners, a private equity firm that partners with consumer brands and other leading investment firms to maximize value by leveraging its unique influencer base of athletes, celebrities, and thought leaders, and is a general partner in LLB Global Fund, an international arbitration fund in partnership with French law firm, Lazareff Le Bars. - 大卫·埃里克·范德文(David Eric Vanderveen)在饮料、营养和技术领域拥有30年的成功业绩记录,在私营和上市公司都引领了颠覆性变革。从2022年直到最近,他担任Nirvana Water Sciences的CEO,在那里他发展了一支行业饮料、功能饮料和补充剂专家团队,以转变品牌、产品组合、上市战略和业务的执行。从2002年到2015年,Vanderveen先生是XS Worldwide的创始人和首席执行官,该公司拥有能量饮料和运动营养产品组合。XS与安利公司合作,成为全球最大直销商增长最快的业务板块和品类,年销售额超过4亿美元,在60多个国家进行分销。XS于2015年被出售给安利,范德文先生在安利担任XS品牌副总裁兼全球总经理,在2018年实现了最大收益。Vanderveen先生还是RX3 Growth Partners的顾问和有限合伙人,RX3 Growth Partners是一家私募股权公司,与消费品牌和其他领先的投资公司合作,通过利用其独特的运动员、名人和思想领袖的影响者基础实现价值最大化,并且是LLB Global Fund的普通合伙人,这是一家与法国律师事务所Lazareff Le Bars合作的国际仲裁基金。
- David Eric Vanderveen,has had a successful 30-year track record in beverage, nutrition, and technology, leading disruptive change at both private and public companies. From 2022 until recently, he was CEO of Nirvana Water Sciences, where he developed a team of industry beverage, functional beverage, and supplement experts to transform the brand, product portfolio, go-to-market strategy, and execution of the business. From 2002 to 2015, Mr. Vanderveen was the founder and CEO of XS Worldwide, a company with a portfolio of energy drinks and sports nutrition products. XS partnered with Amway Corporation and became the fastest-growing business segment and category for the world's largest direct seller, reaching annual sales over $400 million with distribution in more than 60 countries. XS was sold to Amway in 2015, where Mr. Vanderveen served as Vice President and Global General Manager for the XS brand, achieving maximum earn-out through 2018. Mr. Vanderveen is also an advisor and limited partner at RX3 Growth Partners, a private equity firm that partners with consumer brands and other leading investment firms to maximize value by leveraging its unique influencer base of athletes, celebrities, and thought leaders, and is a general partner in LLB Global Fund, an international arbitration fund in partnership with French law firm, Lazareff Le Bars.
- Chiu Wing Kwan Winnie
-
Chiu Wing Kwan Winnie,自2011年11月起担任Dorsett Hospitality International的董事长兼执行董事,该公司是一家全球酒店集团,足迹遍布全球22个主要城市,旗下酒店超过60家,自2024年1月起担任Far East Consortium International Limited(HKEX:0035)联席董事总经理,自2015年6月起担任AGORA Hospitality Group Co.,Ltd(TYO:9704)董事长。赵女士亦曾担任多个政府及社区服务职务,自2023年起担任Mega艺术及文化活动委员会委员,自2023年起担任香港财富遗产学院委员,自2022年起担任职业训练局及香港大学校董会委员,自2014年起担任新加坡管理大学国际顾问理事会中国区委员及香港中文大学吴议孙书院校监委员会委员。Chiu女士还是帝盛投资团队和她自己的家族办公室的负责人、Beyond Ventures和Astera Private Credit Fund的普通合伙人、AEF(阿里巴巴创业者基金)大湾区基金和领先风险投资公司Gobi Partners的投资委员会成员。
Chiu Wing Kwan Winnie,has served as the Chairman and Executive Director of Dorsett Hospitality International, a global hospitality group with a footprint in 22 major cities worldwide and over 60 hotels, since November 2011, the Joint Managing Director of Far East Consortium International Limited (HKEx: 0035) since January 2024, and the Chairperson of AGORA Hospitality Group Co., Ltd (TYO: 9704) since June 2015. Ms. Chiu has also served in various government and community service capacities and is a Committee Member of Mega Arts and Cultural Events Committee since 2023, Hong Kong Academy for Wealth Legacy since 2023, Council Member of Vocational Training Council and University of Hong Kong since 2022, Member of the Singapore Management University International Advisory Council in China and Member of the Committee of Overseers of Wu Yee Sun College of Chinese University of Hong Kong since 2014. Ms. Chiu is also the head of the Dorsett Investment team and her own family office, the General Partner of Beyond Ventures and Astera Private Credit Fund, a member of the investment committee of the AEF (Alibaba Entrepreneurs Fund) Greater Bay Area Fund and leading venture capital firm Gobi Partners. - Chiu Wing Kwan Winnie,自2011年11月起担任Dorsett Hospitality International的董事长兼执行董事,该公司是一家全球酒店集团,足迹遍布全球22个主要城市,旗下酒店超过60家,自2024年1月起担任Far East Consortium International Limited(HKEX:0035)联席董事总经理,自2015年6月起担任AGORA Hospitality Group Co.,Ltd(TYO:9704)董事长。赵女士亦曾担任多个政府及社区服务职务,自2023年起担任Mega艺术及文化活动委员会委员,自2023年起担任香港财富遗产学院委员,自2022年起担任职业训练局及香港大学校董会委员,自2014年起担任新加坡管理大学国际顾问理事会中国区委员及香港中文大学吴议孙书院校监委员会委员。Chiu女士还是帝盛投资团队和她自己的家族办公室的负责人、Beyond Ventures和Astera Private Credit Fund的普通合伙人、AEF(阿里巴巴创业者基金)大湾区基金和领先风险投资公司Gobi Partners的投资委员会成员。
- Chiu Wing Kwan Winnie,has served as the Chairman and Executive Director of Dorsett Hospitality International, a global hospitality group with a footprint in 22 major cities worldwide and over 60 hotels, since November 2011, the Joint Managing Director of Far East Consortium International Limited (HKEx: 0035) since January 2024, and the Chairperson of AGORA Hospitality Group Co., Ltd (TYO: 9704) since June 2015. Ms. Chiu has also served in various government and community service capacities and is a Committee Member of Mega Arts and Cultural Events Committee since 2023, Hong Kong Academy for Wealth Legacy since 2023, Council Member of Vocational Training Council and University of Hong Kong since 2022, Member of the Singapore Management University International Advisory Council in China and Member of the Committee of Overseers of Wu Yee Sun College of Chinese University of Hong Kong since 2014. Ms. Chiu is also the head of the Dorsett Investment team and her own family office, the General Partner of Beyond Ventures and Astera Private Credit Fund, a member of the investment committee of the AEF (Alibaba Entrepreneurs Fund) Greater Bay Area Fund and leading venture capital firm Gobi Partners.
高管简历
中英对照 |  中文 |  英文- Yeung Danny Sheng Wu
Yeung Danny 吴胜,是联合创始人。自2014年业务启动以来,杨先生一直担任首席执行官和董事。杨先生进入医疗保健的旅程始于利用他广泛的创业生涯为社会带来影响。从第一天起,杨先生的愿景就是始终将Prenetics Global Limited打造成一家全球性的健康集团,招募最优秀的人才,并给予每个人掌控自身健康的力量。杨先生认为,医疗保健的未来是让医疗保健去中心化,让医疗保健更接近全球数百万人。在共同创立Prenetics Global Limited公司之前,Yeung先生是SXE Ventures的创始合伙人,曾领导对基因检测公司和Honey Science的多项投资,后者于2019年被PayPal以40亿美元收购。杨先生还曾在2010年创立uBuyiBuy,该公司随后被Groupon收购。在2014年初离开Groupon之前,杨先生曾担任Groupon东亚地区的首席执行官,使其成为该地区最大的电子商务公司。杨先生的创业之旅始于25岁,当时他冒险将香港甜品连锁店“回流山”特许经营进入美国。在退出汇流山后,杨先生成功涉足款待家具,并与MGM在全球范围内执行了数百万美元的项目。
Yeung Danny Sheng Wu,is co-founder. Since business inception in 2014, Mr. Yeung has served as Chief Executive Officer and director. Mr. Yeung's journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung's vision from day 1 was to always turn Prenetics Global Limited into a global health group, recruiting the best talent, and to give everyone the power to be in control of their own health. Prior to co-founding Prenetics Global Limited company, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by PayPal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung's entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain "Hui Lau Shan" into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi- million-dollar projects with MGM globally.- Yeung Danny 吴胜,是联合创始人。自2014年业务启动以来,杨先生一直担任首席执行官和董事。杨先生进入医疗保健的旅程始于利用他广泛的创业生涯为社会带来影响。从第一天起,杨先生的愿景就是始终将Prenetics Global Limited打造成一家全球性的健康集团,招募最优秀的人才,并给予每个人掌控自身健康的力量。杨先生认为,医疗保健的未来是让医疗保健去中心化,让医疗保健更接近全球数百万人。在共同创立Prenetics Global Limited公司之前,Yeung先生是SXE Ventures的创始合伙人,曾领导对基因检测公司和Honey Science的多项投资,后者于2019年被PayPal以40亿美元收购。杨先生还曾在2010年创立uBuyiBuy,该公司随后被Groupon收购。在2014年初离开Groupon之前,杨先生曾担任Groupon东亚地区的首席执行官,使其成为该地区最大的电子商务公司。杨先生的创业之旅始于25岁,当时他冒险将香港甜品连锁店“回流山”特许经营进入美国。在退出汇流山后,杨先生成功涉足款待家具,并与MGM在全球范围内执行了数百万美元的项目。
- Yeung Danny Sheng Wu,is co-founder. Since business inception in 2014, Mr. Yeung has served as Chief Executive Officer and director. Mr. Yeung's journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung's vision from day 1 was to always turn Prenetics Global Limited into a global health group, recruiting the best talent, and to give everyone the power to be in control of their own health. Prior to co-founding Prenetics Global Limited company, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by PayPal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung's entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain "Hui Lau Shan" into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi- million-dollar projects with MGM globally.
- Tzang Chi Hung Lawrence
Tzang Chi Hung Lawrence,是联合创始人。自2014年创立以来,Tzang博士一直担任首席科学官和董事,Tzang博士负责监督新检测产品和服务的开发、评估和实施、实验室自动化、实验室设置的监督以及医学实验室认可的运营和治理。Tzang博士在诊断测试方面拥有超过20年的行业经验,被公认为基于DNA的分子诊断技术的领导者。Tzang博士自2013年起担任医学检验技术专家委员会注册医学检验技术专家I,自2011年起担任香港行为与神经遗传学学会创始成员及秘书,自2008年起担任香港分子诊断科学学会会士。Tzang博士于2003年至2009年在香港城市大学生物与化学系获得博士后研究奖学金。Tzang博士分别于2003年和1996年获得香港城市大学分子生物学博士学位和应用化学学士学位。
Tzang Chi Hung Lawrence,is co-founder. Since founding in 2014, Dr. Tzang has served as Chief Scientific Officer and director, where Dr. Tzang oversees development, evaluation and implementation of new testing products and services, laboratory automation, supervision of laboratory setup and operation and governance of medical laboratory accreditation. Dr. Tzang has over 20 years industry experience in diagnostic testing and is recognized as a leader in DNA-based molecular diagnostic techniques. Dr. Tzang has been a registered Medical Laboratory Technologist I at Board of Medical Laboratory Technologist since 2013, a founding member and secretary at the Hong Kong Society for Behavioral and Neural Genetics since 2011 and a fellow of the Hong Kong Society for Molecular Diagnostic Sciences since 2008. Dr. Tzang received his post-doctoral research fellowship at the Department of Biology & Chemistry of the City University of Hong Kong from 2003 to 2009. Dr. Tzang received a Ph.D. in Molecular Biology and a B.Sc. in Applied Chemistry from the City University of Hong Kong in 2003 and 1996, respectively.- Tzang Chi Hung Lawrence,是联合创始人。自2014年创立以来,Tzang博士一直担任首席科学官和董事,Tzang博士负责监督新检测产品和服务的开发、评估和实施、实验室自动化、实验室设置的监督以及医学实验室认可的运营和治理。Tzang博士在诊断测试方面拥有超过20年的行业经验,被公认为基于DNA的分子诊断技术的领导者。Tzang博士自2013年起担任医学检验技术专家委员会注册医学检验技术专家I,自2011年起担任香港行为与神经遗传学学会创始成员及秘书,自2008年起担任香港分子诊断科学学会会士。Tzang博士于2003年至2009年在香港城市大学生物与化学系获得博士后研究奖学金。Tzang博士分别于2003年和1996年获得香港城市大学分子生物学博士学位和应用化学学士学位。
- Tzang Chi Hung Lawrence,is co-founder. Since founding in 2014, Dr. Tzang has served as Chief Scientific Officer and director, where Dr. Tzang oversees development, evaluation and implementation of new testing products and services, laboratory automation, supervision of laboratory setup and operation and governance of medical laboratory accreditation. Dr. Tzang has over 20 years industry experience in diagnostic testing and is recognized as a leader in DNA-based molecular diagnostic techniques. Dr. Tzang has been a registered Medical Laboratory Technologist I at Board of Medical Laboratory Technologist since 2013, a founding member and secretary at the Hong Kong Society for Behavioral and Neural Genetics since 2011 and a fellow of the Hong Kong Society for Molecular Diagnostic Sciences since 2008. Dr. Tzang received his post-doctoral research fellowship at the Department of Biology & Chemistry of the City University of Hong Kong from 2003 to 2009. Dr. Tzang received a Ph.D. in Molecular Biology and a B.Sc. in Applied Chemistry from the City University of Hong Kong in 2003 and 1996, respectively.
- Lo Hoi Chun
罗海春,自2018年起担任首席财务官。在加入之前,Lo先生曾在花旗集团的亚太太平洋投资银行团队担任副总裁,在该团队中广泛参与亚洲和美国的首次公开发行股票交易、配售、债务发行以及跨境并购业务。此前,Lo先生是安永会计师事务所的审计师。Lo先生获得耶鲁大学管理学院工商管理硕士学位、伦敦政治经济学院会计和金融理学硕士学位以及香港浸会大学会计学学士学位。卢先生为香港会计师公会会士、英格兰及威尔士特许会计师公会(ICAEW)特许会计师及CFA章程持有人。他在ICAEW香港委员会任职。
Lo Hoi Chun,has served as Chief Financial Officer since 2018. Prior to joining, Mr. Lo served as the Vice President in the Asia Pacific Investment Banking team of Citigroup, where he worked extensively on initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the U.S. Previously, Mr. Lo was an auditor with Ernst & Young. Mr. Lo received a Master of Business Administration from Yale University's School of Management, a Master of Science in Accounting and Finance from the London School of Economics and Political Science and a bachelor's degree in Accounting from Hong Kong Baptist University. Mr. Lo is a Fellow of the Hong Kong Institute of Certified Public Accountants, a Chartered Accountant of the Institute of Chartered Accountants in England and Wales (ICAEW) and a CFA Charter holder. He serves on the Hong Kong Committee of ICAEW.- 罗海春,自2018年起担任首席财务官。在加入之前,Lo先生曾在花旗集团的亚太太平洋投资银行团队担任副总裁,在该团队中广泛参与亚洲和美国的首次公开发行股票交易、配售、债务发行以及跨境并购业务。此前,Lo先生是安永会计师事务所的审计师。Lo先生获得耶鲁大学管理学院工商管理硕士学位、伦敦政治经济学院会计和金融理学硕士学位以及香港浸会大学会计学学士学位。卢先生为香港会计师公会会士、英格兰及威尔士特许会计师公会(ICAEW)特许会计师及CFA章程持有人。他在ICAEW香港委员会任职。
- Lo Hoi Chun,has served as Chief Financial Officer since 2018. Prior to joining, Mr. Lo served as the Vice President in the Asia Pacific Investment Banking team of Citigroup, where he worked extensively on initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the U.S. Previously, Mr. Lo was an auditor with Ernst & Young. Mr. Lo received a Master of Business Administration from Yale University's School of Management, a Master of Science in Accounting and Finance from the London School of Economics and Political Science and a bachelor's degree in Accounting from Hong Kong Baptist University. Mr. Lo is a Fellow of the Hong Kong Institute of Certified Public Accountants, a Chartered Accountant of the Institute of Chartered Accountants in England and Wales (ICAEW) and a CFA Charter holder. He serves on the Hong Kong Committee of ICAEW.
- Senthil Kumar Sundaram
Senthil Kumar Sundaram,首席临床官,负责监督临床政策。他领导了CircleDNA的科学和临床开发。此外,Sundaram博士领导IM8每日必备和IM8长寿胶囊的临床试验。Sundaram博士因其作为医生兼科学家的经验而受到高度认可,他曾在美国领导过许多基因研究项目。Sundaram博士发现了导致不同神经系统疾病的基因突变和罕见的基因变异Prenetics Global Limited正在开发全外显子组测序等尖端的下一代测序技术。Sundaram博士的研究文章已发表在知名、高影响力期刊,如Neurology、Annals of Neurology、Cerebral Cortex等。Sundaram博士的研究工作由美国国立卫生研究院(NIH)资助。Sundaram博士还担任过不同期刊和NIH研究部分的审评员。
Senthil Kumar Sundaram,is Chief Clinical Officer, and is responsible for overseeing the clinical policies. He led the scientific and clinical development of CircleDNA. In addition, Dr. Sundaram leads the clinical trials of IM8 Daily Essentials and IM8 longevity capsules. Dr. Sundaram is highly recognized for his experience as a physician-scientist, having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases Prenetics Global Limited ing cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram's research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram's research works were funded by the National Institute of Health (NIH), USA. Dr. Sundaram also served as a reviewer of different journals and NIH study sections.- Senthil Kumar Sundaram,首席临床官,负责监督临床政策。他领导了CircleDNA的科学和临床开发。此外,Sundaram博士领导IM8每日必备和IM8长寿胶囊的临床试验。Sundaram博士因其作为医生兼科学家的经验而受到高度认可,他曾在美国领导过许多基因研究项目。Sundaram博士发现了导致不同神经系统疾病的基因突变和罕见的基因变异Prenetics Global Limited正在开发全外显子组测序等尖端的下一代测序技术。Sundaram博士的研究文章已发表在知名、高影响力期刊,如Neurology、Annals of Neurology、Cerebral Cortex等。Sundaram博士的研究工作由美国国立卫生研究院(NIH)资助。Sundaram博士还担任过不同期刊和NIH研究部分的审评员。
- Senthil Kumar Sundaram,is Chief Clinical Officer, and is responsible for overseeing the clinical policies. He led the scientific and clinical development of CircleDNA. In addition, Dr. Sundaram leads the clinical trials of IM8 Daily Essentials and IM8 longevity capsules. Dr. Sundaram is highly recognized for his experience as a physician-scientist, having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases Prenetics Global Limited ing cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram's research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram's research works were funded by the National Institute of Health (NIH), USA. Dr. Sundaram also served as a reviewer of different journals and NIH study sections.
- Joel Neoh
Joel Neoh是CircleDNA的首席消费者官兼董事总经理。他是一位连续创业者和技术主管,拥有超过15年的顶级领导和董事会经验。他在消费技术领域的经验涉及金融科技、电子商务、数字媒体和健康与保健等领域。最近,他是FAve的创始人,这是一家由红杉资本支持、被独角兽公司Pine Labs收购的东南亚领先金融科技平台。Neoh先生在加速为数百万消费者和商家提供数字支付和金融服务方面发挥了重要作用。此前,他是GroupsMore的创始人,该公司已被Groupon收购。在Groupon期间,他领导着该公司的亚太业务,监管着2000多名员工。Neoh先生的创业之旅始于共同创立马来西亚最大的数字新闻平台之一Says.com。他还是马来西亚公司董事协会的董事会董事,促进公司治理的卓越。
Joel Neoh,is Chief Consumer Officer and Managing Director for CircleDNA. He is a serial entrepreneur and technology executive with over 15 years of top-flight leadership and board experience. His experience in consumer technology spans sectors such as fintech, e-commerce, digital media, and health & wellness. Most recently, he was the founder of Fave, a leading Southeast Asian fintech platform backed by Sequoia Capital and acquired by Pine Labs, a unicorn company. Mr. Neoh has been instrumental in accelerating digital payments and financial services for millions of consumers and merchants. Previously, he was the founder of GroupsMore, which was acquired by Groupon. While at Groupon, he headed up its Asia Pacific business, overseeing more than 2,000 employees. Mr. Neoh's entrepreneurial journey started out by co-founding Says.com, one of Malaysia's largest digital news platforms. He is also a Board Director for the Institute of Corporate Directors Malaysia, promoting excellence in corporate governance.- Joel Neoh是CircleDNA的首席消费者官兼董事总经理。他是一位连续创业者和技术主管,拥有超过15年的顶级领导和董事会经验。他在消费技术领域的经验涉及金融科技、电子商务、数字媒体和健康与保健等领域。最近,他是FAve的创始人,这是一家由红杉资本支持、被独角兽公司Pine Labs收购的东南亚领先金融科技平台。Neoh先生在加速为数百万消费者和商家提供数字支付和金融服务方面发挥了重要作用。此前,他是GroupsMore的创始人,该公司已被Groupon收购。在Groupon期间,他领导着该公司的亚太业务,监管着2000多名员工。Neoh先生的创业之旅始于共同创立马来西亚最大的数字新闻平台之一Says.com。他还是马来西亚公司董事协会的董事会董事,促进公司治理的卓越。
- Joel Neoh,is Chief Consumer Officer and Managing Director for CircleDNA. He is a serial entrepreneur and technology executive with over 15 years of top-flight leadership and board experience. His experience in consumer technology spans sectors such as fintech, e-commerce, digital media, and health & wellness. Most recently, he was the founder of Fave, a leading Southeast Asian fintech platform backed by Sequoia Capital and acquired by Pine Labs, a unicorn company. Mr. Neoh has been instrumental in accelerating digital payments and financial services for millions of consumers and merchants. Previously, he was the founder of GroupsMore, which was acquired by Groupon. While at Groupon, he headed up its Asia Pacific business, overseeing more than 2,000 employees. Mr. Neoh's entrepreneurial journey started out by co-founding Says.com, one of Malaysia's largest digital news platforms. He is also a Board Director for the Institute of Corporate Directors Malaysia, promoting excellence in corporate governance.